Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2022

View Archived Issues

BLU-945 for treatment-resistant EGFR T790M mutation-driven lung cancer

Medshine Discovery divulges thyroid hormone receptor beta agonists

Galderma discovers JAK-1 inhibitors

New NFE2-related factor 2 activators described by Sanofi

CNRS and collaborators patent acetylcholinesterase reactivators

RemeGen discloses new anti-c-Met antibody-drug conjugates

Telomere to telomere, the human genome is done

Novel humanized HIS-BRGS mouse model to evaluate immune-related kidney toxicities

New orthotopic xenograft breast cancer murine models developed

Humanized mouse model to asses acute toxicity of immune drug treatments

Sosei Heptares presents novel GLP-1 receptor antagonist HTL-0033097

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...